There is a core unmet need in MESI for a potent, high-strength, locally administered and safe therapy Safety Efficacy Illustrative IVT anti-IL-6 monotherapy Systemic immuno- suppressants Steroids Core unmet need open High Fewer complications 39 • Targets both IL-6 and VEGF disease drivers • Potential to be disease modifying • High strength • Potent • Minimally invasive • Better safety